Compare Coinbase Global, Inc. (COIN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs TG Therapeutics Inc — how do they compare? Coinbase Global, Inc. trades at $180.21 (market cap $45.38B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Coinbase Global, Inc. is far larger — about 5.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and TG Therapeutics Inc for 16 Days on average.
| COIN | TGTX | |
|---|---|---|
Market Cap | $45.38B | $8.16B |
Volume | 11,013,940 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $387.00 | $59.06 |
52-Week Low | $141.09 | $26.94 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $43.03B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $179.39, up 0.53% today, with a bullish technical signal despite recent earnings misses. Revenue grew to $7.18B in 2025, but net income margin turned negative at -15.72%. The company maintains strong cash flow from operations at $2.43B and holds $9.55B in cash. Recent CFTC approval for derivatives clearing and expanded Citigroup partnership signal strategic expansion.
Outlook remains mixed with 55% analyst buy ratings and a $211.91 price target, but negative profitability and projected 2026 net loss of -$988M pose significant risks. Stock performance hinges on execution in derivatives and stablecoin initiatives amid volatile crypto markets.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
